ArticleBioresources and bioprocessing2025
Whole genome surveying and metabolomic profiling aided navigation of therapeutic plethora of Streptomyces melanogenes WPF1 isolated from Pinus patula rhizosphere.
Article in Bioresources and bioprocessing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhizosphere microbial diversity from Western Ghats remains a relatively less explored source of therapeutic agents. Targeted screening of actinomycetes from an under studied area led to the isolation of 24 actinomycetes from Pinus patula rhizosphere. Screening led to identification of Streptomyces melanogenes WPF1 with strong therapeutic potential. Delineation of the whole genome of WPF1 and metabolic profiling of the partially purified active fraction (PF10) led to confirmation of kinamycin D, oleic acid, palmitic acid and other components. These molecules in unison can be correlated to the recorded biological activities of the active fraction. AntiSMASH analysis of the WPF1 genome identified 26 biosynthetic gene clusters (BGCs) associated with secondary metabolite biosynthesis, including one cluster exhibiting over 97% similarity to known Kinamycin biosynthetic pathway. LC-MS and high-resolution mass spectrometry (HRMS) analyses revealed presence of Kinamycin D in the partially purified fraction PF10. PF10 demonstrated selective antibacterial activity against Gram-positive human pathogens and effectively inhibited their biofilm formation. Additionally, PF10 suppressed the proliferation of cancer cell lines, with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.